TEL AVIV, Israel and BETHESDA, Maryland, Oct. 19, 2018 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that Mr. Eyal Barad, Cannabics Pharmaceuticals’ Co-Founder and CEO, will be in attendance at the 2018 CannMed conference, held at the UCLA Luskin Conference Center, Los Angeles, between October 22nd – 24th , 2018.
CannMed 2018, a Personalized Cannabinoid Medicine Conference, attracts medical cannabis researchers from multiple countries who present their latest findings with regards to the efficacy of treating a variety of conditions with cannabis. Amongst other issues, the conference will also highlight treating cancer with Cannabis.
The event will also feature a panel of speakers including key leaders in medical cannabis research, clinical application, production and clinical trials. Coming on the heels of Cannabics’ public announcement this week of the positive results of its pilot study on advanced cancer patients at the CannX Medical conference in Tel Aviv, the company is excited to interface with other scientists and researchers.
“As a drug discovery company that is focused on cannabinoid-based compositions for effective treatment of cancer and it’s side effects, we welcome the potential in interacting with other scientists and researchers in the field,” said Eyal Barad, CEO and Co-Founder of Cannabics Pharmaceuticals.
About Cannabics Pharmaceuticals
Cannabics Pharmaceuticals Inc. (CNBX) is a U.S public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient’s profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and Cancer.
Disclaimer:
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on July 16th, 2018. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc. which are condoned by the Company must emanate from the Company itself and bear our name as its Source.
